Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-04931-y
Abstract: Current standard-of-care treatment of chronically infected hepatitis C virus (HCV) patients involves direct-acting antivirals (DAA). However, concerns exist regarding the emergence of drug -resistant variants and subsequent treatment failure. In this study, we investigate potential… read more here.
Keywords: plasma liver; treatment; treatment patients; direct acting ... See more keywords
Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Virology"
DOI: 10.1128/jvi.00224-19
Abstract: Although antiretroviral therapy (ART) is highly successful, drug-resistant variants can arise that blunt the efficacy of ART. New inhibitors that are broadly effective against known drug-resistant variants are needed, although such compounds might select for… read more here.
Keywords: resistance mutations; resistant variants; drug resistant; resistance ... See more keywords
Targeting HIV-1 RNase H: N’-(2-Hydroxy-benzylidene)-3,4,5-Trihydroxybenzoylhydrazone as Selective Inhibitor Active against NNRTIs-Resistant Variants
Sign Up to like & getrecommendations! Published in 2020 at "Viruses"
DOI: 10.3390/v12070729
Abstract: HIV-1 infection requires life-long treatment and with 2.1 million new infections/year, faces the challenge of an increased rate of transmitted drug-resistant mutations. Therefore, a constant and timely effort is needed to identify new HIV-1 inhibitors… read more here.
Keywords: inhibitor; rnase; hydroxy benzylidene; resistant variants ... See more keywords